Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab and Spartalizumab in metastatic pancreatic cancer
NCT04581343Phase 1Completed
- Sponsor
- Pancreatic Cancer Action Network
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of canakinumab and spartalizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Pancreatic Cancer Action Network. Primary endpoint: Incidence of Dose Limiting Toxicities at 56 days. Started Nov 2020; status: completed.
02
Drugs
canakinumabspartalizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04581343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581343.